322 related articles for article (PubMed ID: 30796818)
1. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
Anywaine Z; Whitworth H; Kaleebu P; Praygod G; Shukarev G; Manno D; Kapiga S; Grosskurth H; Kalluvya S; Bockstal V; Anumendem D; Luhn K; Robinson C; Douoguih M; Watson-Jones D
J Infect Dis; 2019 Jun; 220(1):46-56. PubMed ID: 30796818
[TBL] [Abstract][Full Text] [Related]
2. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
Mutua G; Anzala O; Luhn K; Robinson C; Bockstal V; Anumendem D; Douoguih M
J Infect Dis; 2019 Jun; 220(1):57-67. PubMed ID: 30796816
[TBL] [Abstract][Full Text] [Related]
3. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
[TBL] [Abstract][Full Text] [Related]
6. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
Barry H; Mutua G; Kibuuka H; Anywaine Z; Sirima SB; Meda N; Anzala O; Eholie S; Bétard C; Richert L; Lacabaratz C; McElrath MJ; De Rosa S; Cohen KW; Shukarev G; Robinson C; Gaddah A; Heerwegh D; Bockstal V; Luhn K; Leyssen M; Douoguih M; Thiébaut R;
PLoS Med; 2021 Oct; 18(10):e1003813. PubMed ID: 34714820
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Manno D; Bangura A; Baiden F; Kamara AB; Ayieko P; Kallon J; Foster J; Conteh M; Connor NE; Koroma B; Njie Y; Borboh P; Keshinro B; Lawal BJ; Kroma MT; Otieno GT; Deen AT; Choi EM; Balami AD; Gaddah A; McLean C; Luhn K; Adetola HH; Deen GF; Samai M; Lowe B; Robinson C; Leigh B; Greenwood B; Watson-Jones D
Lancet Infect Dis; 2023 Mar; 23(3):352-360. PubMed ID: 36273490
[TBL] [Abstract][Full Text] [Related]
9. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
Larivière Y; Matuvanga TZ; Osang'ir BI; Milolo S; Meta R; Kimbulu P; Robinson C; Katwere M; McLean C; Lemey G; Matangila J; Maketa V; Mitashi P; Van Geertruyden JP; Van Damme P; Muhindo-Mavoko H
Lancet Infect Dis; 2024 Jul; 24(7):746-759. PubMed ID: 38552653
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Man-Lik Choi E; Abu-Baker Mustapher G; Omosa-Manyonyi G; Foster J; Anywaine Z; Musila Mutua M; Ayieko P; Vudriko T; Ann Mwangi I; Njie Y; Ayoub K; Mundia Muriuki M; Kasonia K; Edward Connor N; Florence N; Manno D; Katwere M; McLean C; Gaddah A; Luhn K; Lowe B; Greenwood B; Robinson C; Anzala O; Kaleebu P; Watson-Jones D;
Vaccine; 2023 Dec; 41(50):7573-7580. PubMed ID: 37981473
[TBL] [Abstract][Full Text] [Related]
11. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Bockstal V; Shukarev G; McLean C; Goldstein N; Bart S; Gaddah A; Anumenden D; Stoop JN; Marit de Groot A; Pau MG; Hendriks J; De Rosa SC; Cohen KW; McElrath MJ; Callendret B; Luhn K; Douoguih M; Robinson C
PLoS One; 2022; 17(10):e0274906. PubMed ID: 36197845
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
Anywaine Z; Barry H; Anzala O; Mutua G; Sirima SB; Eholie S; Kibuuka H; Bétard C; Richert L; Lacabaratz C; McElrath MJ; De Rosa SC; Cohen KW; Shukarev G; Katwere M; Robinson C; Gaddah A; Heerwegh D; Bockstal V; Luhn K; Leyssen M; Thiébaut R; Douoguih M;
PLoS Med; 2022 Jan; 19(1):e1003865. PubMed ID: 35015777
[TBL] [Abstract][Full Text] [Related]
13. Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Goldstein N; McLean C; Gaddah A; Doua J; Keshinro B; Bus-Jacobs L; Hendriks J; Luhn K; Robinson C; Douoguih M
Hum Vaccin Immunother; 2024 Dec; 20(1):2327747. PubMed ID: 38523332
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Choi EM; Lacarra B; Afolabi MO; Ale BM; Baiden F; Bétard C; Foster J; Hamzé B; Schwimmer C; Manno D; D'Ortenzio E; Ishola D; Keita CM; Keshinro B; Njie Y; van Dijck W; Gaddah A; Anumendem D; Lowe B; Vatrinet R; Lawal BJ; Otieno GT; Samai M; Deen GF; Swaray IB; Kamara AB; Kamara MM; Diagne MA; Kowuor D; McLean C; Leigh B; Beavogui AH; Leyssen M; Luhn K; Robinson C; Douoguih M; Greenwood B; Thiébaut R; Watson-Jones D;
Lancet Glob Health; 2023 Nov; 11(11):e1743-e1752. PubMed ID: 37858585
[TBL] [Abstract][Full Text] [Related]
15. Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
Goldstein N; Bockstal V; Bart S; Luhn K; Robinson C; Gaddah A; Callendret B; Douoguih M
J Infect Dis; 2022 Sep; 226(4):595-607. PubMed ID: 32939546
[TBL] [Abstract][Full Text] [Related]
16. Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.
Barry H; Lhomme E; Surénaud M; Nouctara M; Robinson C; Bockstal V; Valea I; Somda S; Tinto H; Meda N; Greenwood B; Thiébaut R; Lacabaratz C
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011500. PubMed ID: 38603720
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
Nyombayire J; Ingabire R; Magod B; Mazzei A; Mazarati JB; Noben J; Katwere M; Parker R; Nsanzimana S; Wall KM; Sayinzoga F; Tichacek A; Robinson C; Hammoud N; Priddy F; Allen S; Karita E
J Infect Dis; 2023 Jan; 227(2):268-277. PubMed ID: 35776140
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation.
Pasin C; Balelli I; Van Effelterre T; Bockstal V; Solforosi L; Prague M; Douoguih M; Thiébaut R
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243126
[TBL] [Abstract][Full Text] [Related]
19. Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.
Kitonsa J; Ggayi AB; Anywaine Z; Kisaakye E; Nsangi L; Basajja V; Nyantaro M; Watson-Jones D; Shukarev G; Ilsbroux I; Robinson C; Kaleebu P
Glob Health Action; 2020 Dec; 13(1):1829829. PubMed ID: 33073737
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
Larivière Y; Garcia-Fogeda I; Zola Matuvanga T; Isekah Osang'ir B; Milolo S; Meta R; Kimbulu P; Robinson C; Katwere M; McLean C; Hens N; Matangila J; Maketa V; Mitashi P; Muhindo-Mavoko H; Van Geertruyden JP; Van Damme P
J Infect Dis; 2024 Apr; 229(4):1068-1076. PubMed ID: 37673423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
